Utilizes proprietary hybrid, experts curated AI platform, leveraging its key partners proprietary data, chem/bio tools, knowledge and expertise to choose highly valuable molecular mechanisms of pathology, to rationally design, accelerate discovery and optimize development of best in class and first in class therapies.

Mobilizes several high value chem/bio models and platforms engineered for rational small molecule design and discovery, including broad classes of oral protein degraders and molecular  glue, protein-protein interaction inhibitors, covalent and reversible binders, synthetic lethality dual inhibitors to solve for superior medical advantages of our drug candidates.

Deploys multi-target and muti-property optimization, predictive pharmacology and biomarker strategy to accelerate non clinical and early clinical development.

Organizes global industrial and academic R&D partnering network leveraging access to functional biology, diversified formulation and manufacturing and highly defined patient cohorts.